TUSTIN, Calif., Dec. 5, 2011 /PRNewswire/ — Radient
Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC),
developer and marketer of the Onko-Sure® In Vitro
Diagnostic (IVD) cancer test, announced today that the two
abstracts it submitted to the 2012 Gastrointestinal Cancers
Symposium (ASCO Conference) were accepted for presentation from
among 730 abstracts submitted. The meeting will be held on January
19-21, 2012 at the Moscone West Building in San Francisco,
California. Dr. Afsaneh Motamed-Khorasani, the Director of Oncology
at Radient, will be presenting the data.
These two abstracts were the results of a collaborative study in
the United States that compared the combined use of Onko-Sure®
with carcinoembryonic antigen (CEA), the routine blood biomarker
for colorectal cancer (CRC), and CEA alone. The clinical trial
included a total of 564 subjects. Radient’s proprietary
Onko-Sure® cancer blood test combined with CEA test were more
effective for the detection of colorectal cancer compared to using
CEA test alone (an increase of 56% in the test sensitivity).
Furthermore, the combined usage of Onko-Sure® and CEA in
monitoring CRC recurrence showed a significant clinical advantage
in terms of sensitivity (an increase of 35% in the test
sensitivity). This was in line with a previous UK study published
in peer reviewed journals in 2010.
Onko-Sure® has already been cleared by the US FDA for the
monitoring of the treatment and recurrence in CRC. “We believe that
Onko-Sure® provides a platform technology that is highly
effective in the monitoring of colorectal cancer. Should an in
vitro diagnostics test increase early detection of CRC recurrence
when used adjunctively with other available diagnostic markers, the
number of annual deaths due to CRC recurrence could be reduced. An
increase in early detection has the potential to lead to an
increased survival rate of patients,” stated Radient
Pharmaceuticals C
‘/>”/>
